NASDAQ:UPC Universe Pharmaceuticals 1/29/2026 Earnings Report $2.69 +0.02 (+0.60%) Closing price 05/14/2026 03:58 PM EasternExtended Trading$2.62 -0.07 (-2.61%) As of 08:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Universe Pharmaceuticals EPS ResultsActual EPS$0.69Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AUniverse Pharmaceuticals Revenue ResultsActual Revenue$8.92 billionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUniverse Pharmaceuticals Announcement DetailsQuarterDate1/29/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Universe Pharmaceuticals Earnings HeadlinesUniverse Pharmaceuticals Incorporation Class AApril 29, 2026 | edition.cnn.comUniverse Pharmaceuticals Sets February 13 Effective Date for Dual-Class Share StructureFebruary 11, 2026 | tipranks.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 15 at 1:00 AM | Brownstone Research (Ad)Universe Pharmaceuticals INC Implements Dual-Class Share Structure on Nasdaq Effective February 13, 2026February 11, 2026 | quiverquant.comQUniverse Pharmaceuticals INC Announces Effective Date of Dual-Class Share StructureFebruary 11, 2026 | globenewswire.comUniverse Pharmaceuticals Inc trading resumesOctober 8, 2025 | msn.comSee More Universe Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Universe Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Universe Pharmaceuticals and other key companies, straight to your email. Email Address About Universe PharmaceuticalsUniverse Pharmaceuticals (NASDAQ:UPC), Inc. is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments. The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action. In parallel, Universe is exploring additional pipeline assets aimed at reducing post-operative scarring and controlling inflammation in anterior segment surgeries. Preclinical studies have demonstrated favorable pharmacokinetics and tissue penetration in animal models, supporting the potential for once-daily dosing regimens. Headquartered in the United Kingdom with a research subsidiary in the United States, Universe Pharmaceuticals maintains collaborations with academic institutions and contract development organizations to accelerate its drug development programs. The company is led by a management team with extensive experience in ophthalmology drug development and regulatory strategy, positioning it to advance its candidates through late-stage clinical trials and toward commercialization.View Universe Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles YETI Rallies After Earnings Beat and Raised OutlookAeluma's Post-Earnings Dip Creates a Buying OpportunityCisco’s Vertical Rally May Still Be in the Early InningsKarman: Defense Darling's Outlook Strengthens After 40% DropHow the 3 Leading Quantum Firms Stack Up After Q1 EarningsNebius Upside Expands as AI Feedback Loop IntensifiesOklo Stock Could Be Ready for Another Massive Run Upcoming Earnings Baidu (5/18/2026)Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
